For the treatment of SLL/CLL, guidelines and research recommend prioritizing Bruton’s tyrosine kinase (BTK) inhibitors for TP53-positive chronic lymphocytic leukemia (7, 22). Here, BTK is linked to B-cell chronic lymphocytic leukemia.